A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma

Genentech

Status: Completed

Conditions: Colorectal Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00097578

AVF2941n

Details and patient eligibility

About

This is an observational study designed to follow patients with metastatic or locally advanced and unresectable colorectal cancer who are receiving Avastin in combination with chemotherapy and whose cancer has been either previously untreated or treated <=4 months prior to enrollment.

Enrollment: 1,953 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed Informed Consent and Authorization document
• Metastatic, or locally advanced and unresectable, adenocarcinoma of the colon or rectum
• Receiving Avastin as a component of first-line chemotherapy
• First-line chemotherapy plus Avastin initiated <=4 months prior to enrollment in the study

Exclusion criteria

• Patients who have contraindications for treatment with Avastin (see the Avastin Package Insert) or who would incur excessive risks with Avastin treatment are ineligible for this study.